tiprankstipranks
Trending News
More News >

Jeffrey Hatfield Insider Profile

4 Followers
Jeffrey Hatfield, CEO, Director at Vitae Pharma, holds 293.90K shares in Vitae Pharma (Ticker: VTAE), holds ― shares in Invivo Therapeutics Holdings (Ticker: NVIVQ), holds ― shares in Viridian Therapeutics (Ticker: VRDN).
tipranks
Jeffrey Hatfield

Jeffrey Hatfield
Vitae Pharma (VTAE)
CEO, Director

Ranked #81,579 out of 100,956 Corporate Insiders

Profitable Transactions

0%
0 out of 2 Profitable Transactions

Average Return

-44.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$189K
100.00%
0.00%
0.00%
0.00%
A breakdown of Jeffrey Hatfield's holdings

Insider Roles

Vir Biotechnology
(VIR)
Director
Viridian Therapeutics
(VRDN)
Director
Larimar Therapeutics
(LRMR)
CEO, Director
aTyr Pharma
(ATYR)
Director
Roles that Jeffrey Hatfield holds in companies

Most Profitable Insider Trade

Stock:
Vitae Pharma
(VTAE)
Rating:Informative Buy
Date:Jan 26, 2015 - Jan 26, 2016
Return:-32.90%
The most profitable trade made by Jeffrey Hatfield

Jeffrey Hatfield's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
VTAE
Vitae Pharma
Oct 25, 2016
Uninformative Sell
5.14M
$6.17M
NVIVQ
Invivo Therapeutics Holdings
Viridian Therapeutics
Director
Larimar Therapeutics
CEO, Director
aTyr Pharma
Director
Vir Biotechnology
Jun 03, 2024
Director
Uninformative Buy
$189.50K
~AMBI
Ambit
List of latest transactions for each holding click on a transaction to see Jeffrey Hatfield's performance on stock

Jeffrey Hatfield insider profile FAQ

What is the percentage of profitable transactions made by Jeffrey Hatfield?
The percentage of profitable transactions made by Jeffrey Hatfield is 0%.
    What is the average return per transaction made by Jeffrey Hatfield?
    The average return per transaction made by Jeffrey Hatfield is -44.60%.
      What stocks does Jeffrey Hatfield hold?
      Jeffrey Hatfield holds: VTAE, NVIVQ, VRDN, LRMR, ATYR, VIR, ~AMBI stocks.
        What was Jeffrey Hatfield’s latest transaction?
        Jeffrey Hatfield latest transaction was an Uninformative Sell of $5.14M.
          What was Jeffrey Hatfield's most profitable transaction?
          Jeffrey Hatfield’s most profitable transaction was an Informative Buy of VTAE stock on January 26, 2015. The return on the trade was -32.90%.
            What is Jeffrey Hatfield's role in Vitae Pharma?
            Jeffrey Hatfield's role in Vitae Pharma is CEO, Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.